参考文献/References:
[1] Pringsheim T,Jette N,Frolkis A,et al.The prevalence of Parkinson's disease:a systematic review and meta-analysis[J].Mov Disord,2014,29(13):1583-1590.
[2] Janda E,Isidoro C,Carresi C,et al.Defective autophagy in Parkinson'sdisease:role of oxidative stress[J].Mol Neurobiol,2012,46(3):639-661.
[3] Deas E,Cremades N,Angelova PR,et al.Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in parkinson'sdisease[J].Antioxid Redox Signal,2015,24(7):376-391.
[4] L(¨overu)E,Deng J,Yu Y,et al.Nrf2-ARE signals mediated the anti-oxidative action of electroacupuncture in an MPTP mouse model of Parkinson's disease[J].Free Radic Res,2015,49(11):1296-1307.
[5] Loeffler DA,Smith LM,Coffey MP,et al.CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations[J].J Neural Transm,2016,123(3):179-187.
[6] Massano J,Bhatia KP.Clinical approach to Parkinson's disease:features,diagnosis,and principles of management[J].Cold Spring Harb Perspect Med,2012,2(6):a008870.
[7] Kieseier BC,Wiendl H.Nrf2 and beyond:deciphering the mode of action offumarates in the inflamed central nervous system[J].Acta Neuropathol,2015,130(2):297-298.
[8] Ruiz S,Pergola PE,Zager RA,et al.Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease[J].Kidney Int,2013,83(6):1029-1041.
[9] Srivastava S,Alfieri A,Siow RC,et al.Temporal and spatial distribution of Nrf2 in rat brain following stroke:quantification of nuclear to cytoplasmic Nrf2 content using a novel immunohistochemical technique[J].J Physiol,2013,591(14):3525-3538.
[10] Sampat R,Young S,Rosen A,et al.Potential mechanisms for lowuric acid in Parkinson disease[J].J Neural Transm,2016,123(4):365-370.
[11] Joshi G,Johnson JA.The Nrf2-ARE pathway:a valuable therapeutic target for the treatment of neurodegenerative diseases[J].Recent Pat CNS Drug Discov,2012,7(3):218-229.
[12] Lin X,Cook TJ,Zabetian CP,et al.DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease[J].Sci Rep,2012,2(50):954.
[13] Jazwa A,Rojo AI,Innamorato NG,et al.Pharmacological targeting of thetranscription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism[J].Antioxid Redox Signal,2011,14(12):2347-2360.
[14] Zhao CY,Wang XL,Peng Y.Role of Nrf2 in neurodegenerative diseases andrecent progress of its activators[J].Acta Pharmaceutica Sinica,2015,50(4):375-384.
[15] Von Otter M,Bergstr(¨overo)m P,Quattrone A,et al.Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease-a multicenter study[J].BMC Med Genet,2014(15):131.
[16] Chen YC,Wu YR,Wu YC,et al.Genetic analysis of NFE2L2 promoter variation in Taiwanese Parkinson's disease[J].Parkinsonism Relat Disord,2013,19(2):247-250.
收稿日期:2017-06-05
修回日期:2017-07-11
相似文献/References:
[1]张宝华a,武 琪b.Nrf2基因启动子rs35652124,rs6706649和rs6721961位点单核苷酸多态性与阿尔茨海默病的相关性研究[J].现代检验医学杂志,2017,32(05):62.[doi:10.3969/j.issn.1671-7414.2017.05.017]
ZHANG Bao-huaa,WU Qib.Association between Nrf2 Gene rs35652124,rs6706649
and rs6721961 Polymorphism and Alzheimer's Disease[J].Journal of Modern Laboratory Medicine,2017,32(06):62.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[2]武 琪a,陈 亮b,张宝华c.帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义[J].现代检验医学杂志,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
WU Qia,CHEN Liangb,ZHANG Bao-huac.Changes and Clinical Significance of Melatonin in Blood
and Cerebrospinal Fluid of Patients with Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(06):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[3]李泽东,詹 贞,刘 忆,等.帕金森病患者血清鳞状细胞癌抗原(SCC-Ag)表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 / j.issn.1671-7414.2019.06.017]
LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(06):70.[doi:10.3969 / j.issn.1671-7414.2019.06.017]
[4]尚天明,毕开湘.唾液 α- 突触核蛋白 (SNCA) 与嗅觉评估在帕金森病早期筛查中的应用研究[J].现代检验医学杂志,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
SHANG Tian-ming,BI Kai-xiang.Application Research of Olfactory Assessment and Salivary SNCA in EarlyScreening of Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
[5]李群英,甄时建,何树光,等.帕金森病患者治疗期间血清miR-153,miR-128b水平表达与非运动症状的相关性研究[J].现代检验医学杂志,2021,36(05):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
LI Qun-ying,ZHEN Shi-jian,HE Shu-guang,et al.Research on Correlation between Expression of Serum miR-153, miR-128bLevels and Non-motor Symptoms in Patients with Parkinson’s DiseaseDuring Treatment Period[J].Journal of Modern Laboratory Medicine,2021,36(06):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
[6]闫 欣,商素亮,李 娜,等.血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究[J].现代检验医学杂志,2022,37(03):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
YAN Xin,SHANG Su-liang,LI Na,et al.Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2022,37(06):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
[7]白 雪,董巧云,赵 丽,等.帕金森病患者血清miR-7 和α-Syn 表达水平与认知功能障碍的相关性研究[J].现代检验医学杂志,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
BAI Xue,DONG Qiaoyun,ZHAO Li,et al.Correlation between Serum miR-7 and α-Syn Expression Levels and Cognitive Impairment in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(06):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
[8]郑德泉,江 华,林锦标,等.帕金森病患者血清NPASDP-4,MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J].现代检验医学杂志,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
ZHENG Dequan,JIANG Hua,LIN Jinbiao,et al.Study on the Diagnostic Value of Serum NPASDP-4 and MBP Level Expression with Cognitive Dysfunction and Severity in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(06):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
[9]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(06):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
[10]曹明月,王 巍,周美宁.LPIN1/PPARA 通过抑制SLC47A1 介导的神经元铁死亡缓解帕金森病模型大鼠病情进展的机制研究[J].现代检验医学杂志,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]
CAO Mingyue,WANG Wei,ZHOU Meining.Mechanism Study on LPIN1/PPARA Alleviating the Progression of Parkinson’s Disease in Rats by Inhibiting SLC47A1-Mediated Ferroptosis of Neurons[J].Journal of Modern Laboratory Medicine,2024,39(06):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]